Search Results - Suzanne E. Dahlberg

Refine Results
  1. 1
    Reply to N. Hanna et al and L. Xie et al

    Reply to N. Hanna et al and L. Xie et al by Suresh S. Ramalingam, Suzanne E. Dahlberg

    Published 2020
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  2. 2
    Cytologic‐histologic correlation of programmed death‐ligand 1 immunohistochemistry in lung carcinomas

    Cytologic‐histologic correlation of programmed death‐ligand 1 immunohistochemistry in lung carcinomas by Eleanor Russell‐Goldman, Sasha Kravets, Suzanne E. Dahlberg, Lynette M. Sholl, Marina Vivero

    Published 2018
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

    Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4... by Suzanne E. Dahlberg, Alan B. Sandler, Julie R. Brahmer, Joan H. Schiller, David H. Johnson

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitis

    Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase‐associated pancreatitis by Susan Kearney, Suzanne E. Dahlberg, Donna E. Levy, Stephan D. Voss, Stephen E. Sallan, Lewis B. Silverman

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

    Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab by Tien Hoang, Suzanne E. Dahlberg, Alan B. Sandler, Julie R. Brahmer, Joan H. Schiller, David H. Johnson

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer

    Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non–Small-Cell Lung Cancer by Adrian G. Sacher, Suzanne E. Dahlberg, Jennifer Heng, Stacy L. Mach, Pasi A. Jänne, Geoffrey R. Oxnard

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  7. 7
    Population-Based Outcomes Following Endovascular and Open Repair of Ruptured Abdominal Aortic Aneurysms

    Population-Based Outcomes Following Endovascular and Open Repair of Ruptured Abdominal Aortic Aneurysms by Kristina A. Giles, Allen D. Hamdan, Frank B. Pomposelli, Mark C. Wyers, Suzanne E. Dahlberg, Marc L. Schermerhorn

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer

    Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer by Alan Sandler, Jing Yi, Suzanne E. Dahlberg, Margaret Kolb, Lisa Wang, Julie Hambleton, Joan H. Schiller, David H. Johnson

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials

    Body Mass Index and Its Association with Clinical Outcomes for Advanced Non–Small-Cell Lung Cancer Patients Enrolled on Eastern Cooperative Oncology Group Clinical Trials by Suzanne E. Dahlberg, Joan H. Schiller, Philip Bonomi, Alan B. Sandler, Julie R. Brahmer, Suresh S. Ramalingam, David H. Johnson

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500)

    A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induct... by Kishan J. Pandya, Suzanne E. Dahlberg, Manuel Hidalgo, Roger B. Cohen, Martin Lee, Joan H. Schiller, David H. Johnson

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501

    Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501 by Leora Horn, Suzanne E. Dahlberg, Alan B. Sandler, Afshin Dowlati, Dennis F. Moore, John R. Murren, Joan H. Schiller

    Published 2009
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

    Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs by W. Marston Linehan, Stephanie Cardarella, Christine Lydon, Suzanne E. Dahlberg, David M. Jackman, Pasi A. Jänne, Bruce E. Johnson

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Paclitaxel and Carboplatin in the Eastern Cooperative Oncology Group Trial 4599

    Sex Differences in Outcome with Bevacizumab Therapy: Analysis of Patients with Advanced-Stage Non-small Cell Lung Cancer Treated with or without Bevacizumab in Combination with Pac... by Julie R. Brahmer, Suzanne E. Dahlberg, Robert J. Gray, Joan H. Schiller, Michael C. Perry, Alan Sandler, David H. Johnson

    Published 2010
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

    Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI by Mizuki Nishino, Suzanne E. Dahlberg, Stephanie Cardarella, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Pasi A. Jänne, Bruce E. Johnson

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: The ECOG 3598 Study

    Randomized Phase III Study of Thoracic Radiation in Combination With Paclitaxel and Carboplatin With or Without Thalidomide in Patients With Stage III Non–Small-Cell Lung Cancer: T... by Tien Hoang, Suzanne E. Dahlberg, Joan H. Schiller, Minesh P. Mehta, Thomas J. FitzGerald, Steven A. Belinsky, David H. Johnson

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival

    Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival by Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, Tetsuro Araki, Christine Lydon, David M. Jackman, Michael S. Rabin, Hiroto Hatabu, Bruce E. Johnson

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome

    Tumor Response Dynamics of Advanced Non–small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome by Mizuki Nishino, Suzanne E. Dahlberg, Anika E. Adeni, Christine Lydon, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi, Mark M. Awad

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

    Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer by Peter Lo, Suzanne E. Dahlberg, Mizuki Nishino, Bruce E. Johnson, Lecia V. Sequist, David M. Jackman, Pasi A. Jänne, Geoffrey R. Oxnard

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Fate of the contralateral limb after lower extremity amputation

    Fate of the contralateral limb after lower extremity amputation by Julia Glaser, Rodney P. Bensley, Rob Hurks, Suzanne E. Dahlberg, Allen D. Hamdan, Mark C. Wyers, Elliot L. Chaikof, Marc L. Schermerhorn

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors

    Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors by Mizuki Nishino, Stephanie Cardarella, Suzanne E. Dahlberg, David M. Jackman, Nikhil H. Ramaiya, Hiroto Hatabu, Michael S. Rabin, Pasi A. Jnne, Bruce E. Johnson

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: